Publisher Correction: Truncated FGFR2 is a clinically actionable oncogene in multiple cancers (Nature, (2022), 608, 7923, (609-617), 10.1038/s41586-022-05066-5)

Daniel Zingg; Jinhyuk Bhin; Julia Yemelyanenko; Sjors M. Kas; Frank Rolfs; Catrin Lutz; Jessica K. Lee; Sjoerd Klarenbeek; Ian M. Silverman; Stefano Annunziato; Chang S. Chan; Sander R. Piersma; Timo Eijkman; Madelon Badoux; Ewa Gogola; Bjørn Siteur; Justin Sprengers; Bim de Klein; Richard R. de Goeij-de Haas; Gregory M. Riedlinger; Hua Ke; Russell Madison; Anne Paulien Drenth; Eline van der Burg; Eva Schut; Linda Henneman; Martine H. van Miltenburg; Natalie Proost; Huiling Zhen; Ellen Wientjens; Roebi de Bruijn; Julian R. de Ruiter; Ute Boon; Renske de Korte-Grimmerink; Bastiaan van Gerwen; Luis Féliz; Ghassan K. Abou-Alfa; Jeffrey S. Ross; Marieke van de Ven; Sven Rottenberg; Edwin Cuppen; Anne Vaslin Chessex; Siraj M. Ali; Timothy C. Burn; Connie R. Jimenez; Shridar Ganesan; Lodewyk F. A. Wessels; Jos Jonkers

doi:https://doi.org/10.1038/s41586-022-05287-8

Publisher Correction: Truncated FGFR2 is a clinically actionable oncogene in multiple cancers (Nature, (2022), 608, 7923, (609-617), 10.1038/s41586-022-05066-5)

Daniel Zingg, Jinhyuk Bhin, Julia Yemelyanenko, Sjors M. Kas, Frank Rolfs, Catrin Lutz, Jessica K. Lee, Sjoerd Klarenbeek, Ian M. Silverman, Stefano Annunziato, Chang S. Chan, Sander R. Piersma, Timo Eijkman, Madelon Badoux, Ewa Gogola, Bjørn Siteur, Justin Sprengers, Bim de Klein, Richard R. de Goeij-de Haas, Gregory M. RiedlingerHua Ke, Russell Madison, Anne Paulien Drenth, Eline van der Burg, Eva Schut, Linda Henneman, Martine H. van Miltenburg, Natalie Proost, Huiling Zhen, Ellen Wientjens, Roebi de Bruijn, Julian R. de Ruiter, Ute Boon, Renske de Korte-Grimmerink, Bastiaan van Gerwen, Luis Féliz, Ghassan K. Abou-Alfa, Jeffrey S. Ross, Marieke van de Ven, Sven Rottenberg, Edwin Cuppen, Anne Vaslin Chessex, Siraj M. Ali, Timothy C. Burn, Connie R. Jimenez, Shridar Ganesan, Lodewyk F. A. Wessels, Jos Jonkers

Research output: Contribution to journal › Comment/Letter to the editor › Academic

1 Citation (Scopus)

Abstract

This paper was originally published under a standard Springer Nature license (

Original language	English
Pages (from-to)	E13
Journal	NATURE
Volume	609
Issue number	7929
Early online date	2022
DOIs	https://doi.org/10.1038/s41586-022-05287-8
Publication status	Published - 29 Sept 2022

Access to Document

https://doi.org/10.1038/s41586-022-05287-8

Cite this

Zingg, D., Bhin, J., Yemelyanenko, J., Kas, S. M., Rolfs, F., Lutz, C., Lee, J. K., Klarenbeek, S., Silverman, I. M., Annunziato, S., Chan, C. S., Piersma, S. R., Eijkman, T., Badoux, M., Gogola, E., Siteur, B., Sprengers, J., de Klein, B., de Goeij-de Haas, R. R., ... Jonkers, J. (2022). Publisher Correction: Truncated FGFR2 is a clinically actionable oncogene in multiple cancers (Nature, (2022), 608, 7923, (609-617), 10.1038/s41586-022-05066-5). NATURE, 609(7929), E13. https://doi.org/10.1038/s41586-022-05287-8

@article{4027f8d5f0c34f069a9c369a727baba4,

title = "Publisher Correction: Truncated FGFR2 is a clinically actionable oncogene in multiple cancers (Nature, (2022), 608, 7923, (609-617), 10.1038/s41586-022-05066-5)",

abstract = "This paper was originally published under a standard Springer Nature license (",

author = "Daniel Zingg and Jinhyuk Bhin and Julia Yemelyanenko and Kas, {Sjors M.} and Frank Rolfs and Catrin Lutz and Lee, {Jessica K.} and Sjoerd Klarenbeek and Silverman, {Ian M.} and Stefano Annunziato and Chan, {Chang S.} and Piersma, {Sander R.} and Timo Eijkman and Madelon Badoux and Ewa Gogola and Bj{\o}rn Siteur and Justin Sprengers and {de Klein}, Bim and {de Goeij-de Haas}, {Richard R.} and Riedlinger, {Gregory M.} and Hua Ke and Russell Madison and Drenth, {Anne Paulien} and {van der Burg}, Eline and Eva Schut and Linda Henneman and {van Miltenburg}, {Martine H.} and Natalie Proost and Huiling Zhen and Ellen Wientjens and {de Bruijn}, Roebi and {de Ruiter}, {Julian R.} and Ute Boon and {de Korte-Grimmerink}, Renske and {van Gerwen}, Bastiaan and Luis F{\'e}liz and Abou-Alfa, {Ghassan K.} and Ross, {Jeffrey S.} and {van de Ven}, Marieke and Sven Rottenberg and Edwin Cuppen and Chessex, {Anne Vaslin} and Ali, {Siraj M.} and Burn, {Timothy C.} and Jimenez, {Connie R.} and Shridar Ganesan and Wessels, {Lodewyk F. A.} and Jos Jonkers",

note = "Publisher Copyright: {\textcopyright} 2022, The Author(s).",

year = "2022",

month = sep,

day = "29",

doi = "https://doi.org/10.1038/s41586-022-05287-8",

language = "English",

volume = "609",

pages = "E13",

journal = "NATURE",

issn = "0028-0836",

publisher = "Nature Publishing Group",

number = "7929",

}

Zingg, D, Bhin, J, Yemelyanenko, J, Kas, SM, Rolfs, F, Lutz, C, Lee, JK, Klarenbeek, S, Silverman, IM, Annunziato, S, Chan, CS, Piersma, SR, Eijkman, T, Badoux, M, Gogola, E, Siteur, B, Sprengers, J, de Klein, B, de Goeij-de Haas, RR, Riedlinger, GM, Ke, H, Madison, R, Drenth, AP, van der Burg, E, Schut, E, Henneman, L, van Miltenburg, MH, Proost, N, Zhen, H, Wientjens, E, de Bruijn, R, de Ruiter, JR, Boon, U, de Korte-Grimmerink, R, van Gerwen, B, Féliz, L, Abou-Alfa, GK, Ross, JS, van de Ven, M, Rottenberg, S, Cuppen, E, Chessex, AV, Ali, SM, Burn, TC, Jimenez, CR, Ganesan, S, Wessels, LFA & Jonkers, J 2022, 'Publisher Correction: Truncated FGFR2 is a clinically actionable oncogene in multiple cancers (Nature, (2022), 608, 7923, (609-617), 10.1038/s41586-022-05066-5)', NATURE, vol. 609, no. 7929, pp. E13. https://doi.org/10.1038/s41586-022-05287-8

TY - JOUR

T1 - Publisher Correction

T2 - Truncated FGFR2 is a clinically actionable oncogene in multiple cancers (Nature, (2022), 608, 7923, (609-617), 10.1038/s41586-022-05066-5)

AU - Zingg, Daniel

AU - Bhin, Jinhyuk

AU - Yemelyanenko, Julia

AU - Kas, Sjors M.

AU - Rolfs, Frank

AU - Lutz, Catrin

AU - Lee, Jessica K.

AU - Klarenbeek, Sjoerd

AU - Silverman, Ian M.

AU - Annunziato, Stefano

AU - Chan, Chang S.

AU - Piersma, Sander R.

AU - Eijkman, Timo

AU - Badoux, Madelon

AU - Gogola, Ewa

AU - Siteur, Bjørn

AU - Sprengers, Justin

AU - de Klein, Bim

AU - de Goeij-de Haas, Richard R.

AU - Riedlinger, Gregory M.

AU - Ke, Hua

AU - Madison, Russell

AU - Drenth, Anne Paulien

AU - van der Burg, Eline

AU - Schut, Eva

AU - Henneman, Linda

AU - van Miltenburg, Martine H.

AU - Proost, Natalie

AU - Zhen, Huiling

AU - Wientjens, Ellen

AU - de Bruijn, Roebi

AU - de Ruiter, Julian R.

AU - Boon, Ute

AU - de Korte-Grimmerink, Renske

AU - van Gerwen, Bastiaan

AU - Féliz, Luis

AU - Abou-Alfa, Ghassan K.

AU - Ross, Jeffrey S.

AU - van de Ven, Marieke

AU - Rottenberg, Sven

AU - Cuppen, Edwin

AU - Chessex, Anne Vaslin

AU - Ali, Siraj M.

AU - Burn, Timothy C.

AU - Jimenez, Connie R.

AU - Ganesan, Shridar

AU - Wessels, Lodewyk F. A.

AU - Jonkers, Jos

PY - 2022/9/29

Y1 - 2022/9/29

N2 - This paper was originally published under a standard Springer Nature license (

AB - This paper was originally published under a standard Springer Nature license (

UR - http://www.scopus.com/inward/record.url?scp=85137051534&partnerID=8YFLogxK

U2 - https://doi.org/10.1038/s41586-022-05287-8

DO - https://doi.org/10.1038/s41586-022-05287-8

M3 - Comment/Letter to the editor

C2 - 36050473

SN - 0028-0836

VL - 609

SP - E13

JO - NATURE

JF - NATURE

IS - 7929

ER -

Publisher Correction: Truncated FGFR2 is a clinically actionable oncogene in multiple cancers (Nature, (2022), 608, 7923, (609-617), 10.1038/s41586-022-05066-5)

Abstract

Access to Document

Other files and links

Cite this